NA-Selank Amidate

Mechanism of action

Unstudied for this form. It is assumed to act like Selank, whose own studies (see the Selank entry) report effects on GABA-A signalling, BDNF and enkephalin breakdown. Acetyl and amide caps remove the terminal charges and are used in general to resist exopeptidases; whether they lengthen Selank's action has not been measured.

Primary uses

• Anxiolytic nootropic (research/community use)
• Enhanced Selank analog research
• BDNF modulation studies

Typical dosing

Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Regulatory status

Not approved by any regulatory body. Available through research peptide vendors. Parent compound Selank is approved in Russia.

Status as of this entry's last review, October 4, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.

What we checked

No published study has tested this form of Selank. This section records what can be checked: what the name means chemically, the regulatory status on the date below, what is known about Selank itself, and every search we ran.

Identity, computed

The name describes Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro; NLM MeSH record C100827) with an acetyl group on the N-terminus and an amide at the C-terminus, which together add C2H3N to Selank's formula. An earlier version of this entry printed Selank's own formula, C33H57N11O9, with a mass of 755.9 that matches neither form; both were corrected on October 4, 2026.

Regulatory status, read October 6, 2026

Drugs@FDA: 0 records for “selank”. EMA medicines list: 0 records for “selank”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 86 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on September 27, 2026.

What the maker or sellers claim

Claim, from sellers of research peptides: the acetyl and amide caps make the peptide more resistant to enzymes, better absorbed through the nose and longer acting than Selank. None of this has been measured for this compound.

About Selank, not this derivative

Selank itself is a synthetic seven-residue analogue of tuftsin, a fragment of immunoglobulin G, developed in Russia, where it is approved for generalised anxiety disorder and adjustment disorders; it is not approved by the FDA or EMA. Its studies are summarised on the Selank entry.

Capping both ends of a peptide is a common design step: an acetyl group blocks aminopeptidases, which trim from the N-terminus, and an amide blocks carboxypeptidases, which trim from the C-terminus. It also removes the free amino and carboxyl charges; with Selank's only acidic group gone, the calculator finds no pH at which this form is neutral. Whether it changes how long Selank lasts or how much reaches the brain is unknown.

What we looked for and did not find

No study of the acetylated, amidated form, in any species or cell line; no pharmacokinetic data; no registry record; no regulator record. The two PubMed records matching "selank amide" are 2002 and 2003 rat studies of ordinary Selank.

References

1. [other] No independent publication exists for the acetylated and amidated form; what is known is derived from the Selank literature cited on that entry.

Related peptides

Guides & tools